/

Società

C₂

Non verificato

C₂N Diagnostics, LLC

Di cosa scriviamo

BiotecnologiaIndustriaSaluteSanitàScienza

21 comunicati stampa

Guarda tutti i comunicati

29/07/2026

Industria

Scienza

Psichiatria

Igiene alimentare

Medicina - Varie

Sanità

Biotecnologia

Farmaceutica

Salute

United Kingdom Researchers Integrate C2N’s PrecivityAD2® Blood Test Into the Alzheimer’s Disease Diagnostic Care Pathway

Fonte

C₂N Diagnostics, LLC

Emittente

1.00

0

09/07/2026

Industria

Scienza

Sanità

Vetrine/Shopping

Medicina - Varie

Biotecnologia

Terza età

Salute

Anthem Establishes Coverage of C2N Diagnostics’ PrecivityAD2® Blood Test for Alzheimer's Disease Evaluation

Fonte

C₂N Diagnostics, LLC

Emittente

1.00

0

01/06/2026

Biotecnologia

Sanità

Psichiatria

Salute

Industria

C2N Diagnostics and SouthGenetics Partner to Enable Broader Access to Precivity® Blood Tests for Alzheimer’s Disease Assessment in Latin America, Caribbean

Fonte

C₂N Diagnostics, LLC

Emittente

1.00

0

19/03/2026

Industria

Psichiatria

Sanità

Scienza

Biotecnologia

Vetrine/Shopping

Medicina - Varie

Igiene alimentare

Salute

Farmaceutica

Terza età

C2N Diagnostics Highlights First Use of Its eMTBR-tau243 Plasma Assay in Evoke/Evoke+ Phase 3 Dataset for Prediction of Cognitive and Functional Decline in Patients With Early Symptomatic Alzheimer’s Disease

Fonte

C₂N Diagnostics, LLC

Emittente

1.00

0

11/03/2026

Mercato del lavoro

Industria

Farmaceutica

Sanità

Attrezzature medico-sanitarie

Salute

C2N Diagnostics Enters South Korean Market Through Partnership with BeauBrain Healthcare to Offer Precivity™ Portfolio of Blood Tests to Help Doctors Diagnose Alzheimer’s Disease

Fonte

C₂N Diagnostics, LLC

Emittente

1.00

0

13/11/2025

Psichiatria

Salute

Scienza

Eventi

C2N Diagnostics and WashU Medicine Teams Receive Prestigious Award from Human Proteome Organization

Fonte

C₂N Diagnostics, LLC

Emittente

1.00

0

25/09/2025

Industria

Sanità

Terza età

Medicina - Varie

Scienza

Biotecnologia

Vetrine/Shopping

Salute

New Research Reinforces C2N’s PrecivityAD2™ Blood Test as a Highly Accurate Tool to Detect Brain Amyloid Pathology in Symptomatic Patients

Fonte

C₂N Diagnostics, LLC

Emittente

1.00

0

03/09/2025

Dynamic Growth Leads C2N Diagnostics to Expand St. Louis Headquarters to Meet Global Need for Answers to Alzheimer’s Disease

Fonte

C₂N Diagnostics, LLC

Emittente

1.00

0

25/08/2025

Sanità

Vetrine/Shopping

Medicina - Varie

Biotecnologia

Terza età

Salute

Industria

C2N Diagnostics Expands the PrecivityAD2™ Alzheimer’s Disease Blood Test Intended Use to Patients 50 Years and Older

Fonte

C₂N Diagnostics, LLC

Emittente

1.00

0

07/08/2025

Scienza

Psichiatria

Medicina - Varie

Biotecnologia

Sanità

Farmaceutica

Salute

Mercato del lavoro

Industria

C2N Announces Major Global Expansion, Adds Six New International Partners

Fonte

C₂N Diagnostics, LLC

Emittente

1.00

0

Seguaci

0

Compatibilità

0